Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2024 / Nov / Blood Biomarkers for AMD
Research & Innovations

Blood Biomarkers for AMD

Shanghai-based researchers investigate three metabolite biomarkers for diagnosing and monitoring age-related macular degeneration

By The Ophthalmologist 11/18/2024 3 min read

Share

Original image from Shutterstock.com

Age-related macular degeneration (AMD) can be challenging to diagnose in its early stages – with a reliance on imaging techniques that is not always effective. Now, researchers of a Journal of Advanced Research study have outlined a new approach for identifying and tracking blood-based metabolic biomarkers for AMD.

Using a multicenter cohort study design, involving 547 participants, and a mass spectrometry-based metabolomic workflow combined with machine learning techniques, the team uncovered three metabolites – hypoxanthine, 2-furoylglycine, and 1-hexadecyl-2-azelaoyl-sn-glycero-3-phosphocholine – that were strongly associated with AMD’s onset, severity, and progression.

The resulting three-biomarker panel demonstrated excellent accuracy in distinguishing AMD patients from healthy controls and individuals with other eye diseases. The study also highlighted that these biomarkers are stable in repeated tests and can withstand multiple freeze-thaw cycles without demonstrating any decrease in their levels, making them reliable candidates for clinical use.

The biomarkers also provided the researchers with insights into the AMD’s severity, allowing them to classify the disease into early, intermediate, and advanced stages, in accordance with the classification system used by the Age-Related Eye Disease Study (AREDS).

According to the authors, “This study reveals distinct metabolite variations in the serum of AMD patients, paving the way for the development of the first routine laboratory test for AMD.”

About the Author(s)

The Ophthalmologist

More Articles by The Ophthalmologist

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: